Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Key Terms

precision medicine medical

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

multimodal data technical

Multimodal data is information that combines different types of sources—such as numbers, written reports, photos, audio, and sensor readings—into a single view. For investors it matters because blending these types is like looking at a company with both a microscope and a wide-angle lens: it can reveal risks, trends, or opportunities that a single type of data would miss, improving decision-making, forecasting, and due diligence.

trial design medical

A trial design is the detailed plan for how a clinical study will test a drug, device or therapy — who joins, how people are assigned to treatments, what outcomes are measured, and how long the study runs. Like a blueprint for a building or a recipe for a dish, the design determines how believable and useful the results will be, so investors watch it closely because it shapes the chance of regulatory approval, costs, timelines and commercial prospects.

indication selection medical

Choosing an indication means deciding which disease or medical condition a drug or therapy will be developed and tested to treat. Like picking the most promising market for a new product, this choice shapes how big the potential customer base could be, how long and costly the testing and approval process will run, and how risky the regulatory and commercial outcome might be for investors.

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

real world evidence medical

Data about how a medical product performs in everyday use outside tightly controlled clinical trials, gathered from sources like medical records, insurance claims, patient reports, and device trackers. Investors care because this evidence can change how regulators, doctors and insurers view a product’s safety, effectiveness and value — like seeing how a car holds up on real roads versus a test track, which affects sales, approvals and reimbursement.

oncology medical

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

ai-driven technical

AI-driven describes products, services, processes or decisions that rely on artificial intelligence—software that detects patterns in data and makes predictions or choices without step-by-step human direction. For investors it signals potential for faster growth, lower operating costs or new revenue, but also new risks (model errors, data problems, regulatory limits); think of it like a smart thermostat that can save energy and money but can also misbehave if fed bad information.

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline.

To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real world evidence. The expanded agreement provides Gilead with enterprise-wide access to Tempus’ AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services.

“We are excited to announce this expanded partnership with Tempus that reflects our shared priority of putting patients at the heart of innovation,” said Patrick Loerch, SVP of Clinical Data Science at Gilead Sciences. “By combining Gilead’s scientific expertise with Tempus’ real world data insights in oncology, we aim to maximize generation of key insights to help inform clinical decision making and ultimately improve care for cancer patients.”

“By providing access to the Tempus multimodal data library, we are empowering the Gilead team to further fuel its R&D engine with AI-driven insights,” said Ryan Fukushima, CEO of Tempus Data & Apps. “We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights. This approach helps navigate billions of data points to find the 'signal in the noise,' ultimately increasing the probability of success for life-altering medicines.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ collaboration with Gilead Sciences aimed at building and advancing its oncology pipeline. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409128442/en/

Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.